UDG Healthcare (UDG) Receives GBX 832.63 Consensus PT from Analysts

UDG Healthcare (LON:UDG) has been given a consensus rating of “Hold” by the eight ratings firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is GBX 825.86 ($11.59).

A number of research firms recently issued reports on UDG. Peel Hunt reiterated an “add” rating and set a GBX 880 ($12.35) price objective on shares of UDG Healthcare in a report on Tuesday, December 19th. Liberum Capital reiterated a “hold” rating and set a GBX 884 ($12.41) price objective on shares of UDG Healthcare in a report on Tuesday, January 30th. Jefferies Group reiterated a “hold” rating and set a GBX 820 ($11.51) price objective on shares of UDG Healthcare in a report on Wednesday, January 17th. Numis Securities reiterated a “reduce” rating and set a GBX 765 ($10.74) price objective on shares of UDG Healthcare in a report on Tuesday, January 30th. Finally, Libertas Partners upgraded UDG Healthcare to a “buy” rating and set a GBX 884 ($12.41) price objective for the company in a report on Wednesday, February 7th.

How to Become a New Pot Stock Millionaire

In related news, insider Chris Corbin sold 730,000 shares of the stock in a transaction that occurred on Tuesday, March 13th. The stock was sold at an average price of GBX 870 ($12.21), for a total transaction of £6,351,000 ($8,914,935.43).

Shares of LON:UDG traded up GBX 8.50 ($0.12) during mid-day trading on Friday, reaching GBX 882.50 ($12.39). 727,762 shares of the stock were exchanged, compared to its average volume of 981,360. UDG Healthcare has a one year low of GBX 690 ($9.69) and a one year high of GBX 963 ($13.52).

TRADEMARK VIOLATION NOTICE: This article was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.thelincolnianonline.com/2018/04/15/udg-healthcare-udg-receives-gbx-832-63-consensus-pt-from-analysts.html.

UDG Healthcare Company Profile

UDG Healthcare PLC, formerly United Drug PLC, provides advisory, commercial, clinical, communications and packaging services to the healthcare industry with operations in approximately 24 countries and delivering services in over 50 countries. The Company operates across three divisions: Ashfield, which provides commercialization services for the pharmaceutical and healthcare industry and operates across two areas of activity: advisory & communications services and commercial & clinical services and provides healthcare communications, patient support, audit, advisory, medical information and event management services; Sharp, which provides contract commercial packaging and clinical trial packaging services for the pharmaceutical and biotechnology industries and operates facilities in the United States and Europe; and Aquilant, which provides outsourced sales, marketing, distribution and engineering services to the medical and scientific sectors in the UK, Ireland and the Netherlands.

Analyst Recommendations for UDG Healthcare (LON:UDG)

Receive News & Ratings for UDG Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UDG Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply